AMENDMENTS TO THE SPECIFICATION

Please amend the specification at page 1, lines 7-11, as follows:

This application is a continuation of U.S. patent application Serial No. 09/895,443, filed on June 29, 2001, which issued on February 10, 2004, as U.S. Patent No. 6,689,752B2, the entire contents of which are incorporated by reference herein; which is a continuation of U.S. patent application Serial No. 09/356,931, filed on July 19, 1999, which issued on August 21, 2001, as U.S. Patent No. 6,277,826B1; which is a continuation of U.S. patent application Serial No. 08/920,162, filed on August 27, 1997, which issued on November 16, 1999, as U.S. Patent No. 5,985,242; which, in turn, is a continuation-in-part of U.S. patent application Serial No. 08/897,342, filed on July 21, 1997, now abandoned, the entire contents of which are incorporated by reference herein; which is a continuation-in-part of U.S. patent application Serial No. 08/703,675, filed on August 27, 1996, which issued on October 16, 2001, as U.S. Patent No. 6,303,567B1, the entire contents of which are incorporate by reference herein; which is a continuation-in-part of U.S. patent application Serial No. 08/616,081, filed on March 14, 1996, now abandoned, the entire contents of which are incorporated by reference herein; which is a continuation-in-part of U.S. patent application Serial No. 08/548,998, filed on October 27, 1995, now abandoned, the entire content of which is incorporated by reference herein ~~The entire contents of each of the aforementioned patents and patent applications are hereby incorporated by reference~~.

Please amend the specification at page 50, lines 19-26, as follows:

The above-described CSF stability assay was used to compare the CSF stability of a L-amino acid-based modulator compound (PPI-368, having the structure cholyl-Leu-Val-Phe-Phe-Ala-OH) (SEQ ID NO:34) with an analogous D-amino acid-based peptide acid (PPI-433, having the structure cholyl-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-OH) and an analogous D-amino acid-based peptide amide (PPI-457, having the structure cholyl-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-NH_2) ~~(SEQ ID NO:34)~~. The results, summarized in the bar graph shown in Figure 1, demonstrate that both D-amino acid-based compounds exhibit significantly greater stability in CSF than the L-amino acid-based compound.

Please amend Table IX at page 52, as follows:

Ref. #	N-Term. Mod.	Peptide	C-Term. Mod.	ΔLag 5 μM
PPI-457	Cholyl-	d(LVFFA)	-nh_2	>6
PPI-483	3-Hydroxyphenylacetyl-	d(LVFF)	-nh_2	2.9
PPI-494	Cholyl-	d(LVF)	Phenethy-lamide	1.3
PPI-501	Ac-	d(LVFFA)	-nh_2	1.4
PPI-520	Hyodeoxycholyl-	(LVFFA) (SEQ ID NO:353)	-oh	1.5
PPI-521	Chenodeoxycholyl-	(LVFFA) (SEQ ID NO:363)	-oh	3.6
PPI-522	Ursodeoxycholyl-	(LVFFA) (SEQ ID NO:373)	-oh	1.2
PPI-532	2,4-Dihydroxybenzoyl-	d(LVFFA)	-nh_2	1.7
PPI-535	Glycolyl-	d(LVFFA)	-nh_2	1.3
PPI-536	2-Hydroxycinnamoyl-	d(LVFFA)	-nh_2	1.4
PPI-537	4-Hydroxycinnamoyl-	d(LVFFA)	-nh_2	1.6
PPI-538	3-Hydroxycinnamoyl-	d(LVFFA)	-nh_2	2.0
PPI-539	5-Hydantoinacetyl-	d(LVFFA)	-nh_2	2.4
PPI-543	3,4-Dihydroxycinnamoyl-	d(LVFFA)	-nh_2	1.6
PPI-546	3-Formylbenzoyl-	d(LVFFA)	-nh_2	1.9
PPI-554	2-Formylphenoxyacetyl-	d(LVFFA)	-nh_2	2.6
PPI-555	4-Hydroxy-3-methoxycinnamoyl-	d(LVFFA)	-nh_2	1.7
PPI-568	3,5-Dihydroxy-2-naphthoyl-	d(AFFVL)	-nh_2	>6
PPI-569	3,4-Dihydroxycinnamoyl-	d(AFFVL)	-nh_2	2.6
PPI-584	(±)-Mandelyl-	d(AFFVL)	-nh_2	4.8
PPI-587	4-Hydroxycinnamoyl-	d(AFFVL)	-nh_2	3.7
PPI-592	Glycolyl-	d(AFFLL)	-nh_2	1.8
PPI-593	3,4-Dihydroxycinnamoyl-	d(LFFVL)	-nh_2	2.0
PPI-596	Glycolyl-	d(FFFVL)	-nh_2	3.6
PPI-599	DL-3-(4-Hydroxyphenyl)Lactyl-	d(LVFFA)	-nh_2	1.4
PPI-607	D-3-Phenyllactyl-	d(AFFVL)	-nh_2	3.1
PPI-608	L-3-Phenyllactyl-	d(AFFVL)	-nh_2	>6

PPI-610	3-(2-Hydroxyphenyl)propionyl-	d(AFFVL)	$-nh_2$	4.5
PPI-611	4-(2-Hydroxyphenyl)propionyl-	d(AFFVL)	$-nh_2$	3.2
PPI-612	D-3-Phenyllactyl-	d(FFVL)	$-nh_2$	2.1
PPI-615	3-(2-Hydroxyphenyl)propionyl-	d(FFVL)	$-nh_2$	2.0
PPI-616	3-(4-Hydroxyphenyl)propionyl-	d(FFVL)	$-nh_2$	1.5
PPI-619	Hydrocinnamoyl-	d(FFVL)	-oh	2.0
PPI-629	4-Hydroxybenzoyl-	d(AFFVL)	$-nh_2$	2.9
PPI-635	D-3-Phenyllactyl-	d(FFFVL)	$-nh_2$	2.5
PPI-636	Hydrocinnamoyl-	d(FFFVL)	$-nh_2$	1.7
PPI-643	4-Hydroxybenzoyl-	d(LFFFL)	$-nh_2$	2.2
PPI-644	Ac-	d(LFFFL)	$-nh_2$	2.1
PPI-648	3,7-Dihydroxy-2-naphthoyl-	d(LFFVL)	$-nh_2$	3.1
PPI-649	4-Hydroxyphenylacetyl-	d(LFFVL)	$-nh_2$	5.1
PPI-650	3,7-Dihydroxy-2-naphthoyl-	d(FFFVL)	$-nh_2$	2.2
PPI-651	4-Hydroxyphenylacetyl-	d(FFFVL)	$-nh_2$	2.1